Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

GILEAD SCIENCES, INC.

(885823)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über GILEAD SCIENCES, INC.
22.10.GILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy as a Treatment Optio..
21.10.GILEAD SCIENCES : Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Opti..
21.10.Gilead Sciences, Inc. Presents Long-Term Switch Data Reinforcing Biktarvy as A Treatmen..
21.10.GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy for..
20.10.GILEAD SCIENCES : Announces Decision Not to Pursue Marketing Authorization for Descovy® fo..
19.10.Atea plunges after COVID-19 treatment fails to help patients in study
19.10.Atea se desploma tras un estudio que no muestra eficacia en su tratamiento del COVID
19.10.GILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
19.10.GILEAD SCIENCES : Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis..
19.10.GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
19.10.WALL STREET : entame bien novembre malgré taux et baril à 83$
18.10.GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
18.10.GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
18.10.Gilead Sciences, Inc. Announces the U.S. FDA Approves a New Low-Dose Tablet Dosage form..
18.10.Gilead Says FDA Approves Expanded Indication of Biktarvy for Treatment of HIV-1 in Pedi..
15.10.GILEAD SCIENCES : Says Breast Cancer Therapy Receives Positive Opinion by European Medicin..
15.10.GILEAD SCIENCES : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for..
15.10.Gilead Sciences, Inc.'s Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Trea..
15.10.Gilead's Sacituzumab Govitecan Gets Positive CHMP Opinion in Breast Cancer
14.10.GILEAD SCIENCES : to Release Third Quarter 2021 Financial Results on Thursday, October 28,..
14.10.VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
13.10.PRESS RELEASE : NanoViricides, Inc. Has Filed its -2-
13.10.PRESS RELEASE : NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program ..
11.10.EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
11.10.REGENERON PHARMACEUTICALS : Merck seeks first U.S. authorization for COVID-19 pill
11.10.GILEAD SCIENCES : Merck solicita la autorización de emergencia para su píldora contra el C..
11.10.GILEAD SCIENCES : Merck applies for U.S. emergency authorization of COVID-19 pill
04.10.Tech en ING zetten AEX lager
04.10.Brussel blijft in het rood
04.10.GILEAD SCIENCES : Company Unit's Leukemia Drug Gets FDA Approval
04.10.KBC Securities verlaagt koersdoel Galapagos
04.10.WALL-STREET : optimisme diamétralement à l'opposé de l'Europe
04.10.Voldoende patiënten Galapagos voor DIVERSITY fase 3-studie
02.10.ROCHE : Malaysia in talks to procure Merck's COVID-19 pills
01.10.GILEAD SCIENCES : U.S. FDA Approves Kite's Tecartus® as the First and Only Car T for Adult..
01.10.WALL-STREET : optimisme diamétralement à l'opposé de l'Europe
01.10.Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector
01.10.Merck va demander le feu vert pour une pilule anti-Covid
01.10.ROCHE : Coronavirus-Un traitement de Merck réduit de 50% le risque d'hospitalisation ou de..
30.09.GILEAD SCIENCES : Files Supplemental Biologics License Application for Yescarta in Large B..
30.09.KITE : Submits Supplemental Biologics License Application to U.S. Food and Drug Administra..
30.09.PRESS RELEASE : Phase II/III trial shows Ronapreve(TM) (casirivimab and imdevimab) signifi..
28.09.GILEAD SCIENCES : Marks Fifth Approval for Trodelvy in Metastatic Triple-Negative Breast C..
28.09.DEFENCE THERAPEUTICS IS ADVANCING NE : Dtcff)
27.09.GILEAD SCIENCES : Wins Canada OK on Trodelvy for Triple-Negative Breast Cancer
27.09.GILEAD SCIENCES : Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast ..
27.09.Gilead Announces Fifth Approval for Trodelvy in Metastatic Triple-Negative Breast Cance..
27.09.GILEAD SCIENCES : COVID SCIENCE-Protein found on infected cells protects virus from immune..
27.09.GILEAD SCIENCES : Trodelvy Product Now Recommended As Triple-Negative Breast Cancer Treatm..
27.09.GILEAD SCIENCES : Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Gui..
27.09.GILEAD SCIENCES : Pfizer begins study of oral drug for prevention of COVID-19
23.09.GILEAD SCIENCES : Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in Hi..
22.09.GILEAD SCIENCES : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Stud..
22.09.BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
22.09.GILEAD SCIENCES : Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in H..
22.09.Gilead Sciences, Inc. Announces Positive Results from A Phase 3 Randomized, Double-Blin..
20.09.GILEAD SCIENCES : to Present Latest Antiviral Research Data Addressing Urgent Global Needs..
20.09.Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infe..
17.09.GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard of Care in..
17.09.GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic Triple-Nega..
17.09.Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier ..
16.09.GRITSTONE BIO : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5% After-Ho..
16.09.VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
16.09.GILEAD SCIENCES' : Late-Stage Study Shows Breast Cancer Drug May Improve Overall Survival
16.09.GILEAD SCIENCES : Trodelvy® Significantly Improved Quality of Life Over Standard of Care i..
16.09.GILEAD SCIENCES : New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Neg..
16.09.Gilead Sciences, Inc Announces New Data Demonstrate Trodelvy Survival Benefit in Metast..
16.09.Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study
16.09.Gritstone bio, Inc. announced that it expects to receive $55 million in funding from Fr..
13.09.GILEAD SCIENCES : to Present New Data at ESMO Congress 2021 Reinforcing the Practice-chang..
10.09.WALL STREET : s'essouffle au final, mais repli sans intensité
09.09.WALL STREET : s'essouffle au final, mais repli sans intensité
01.09.GILEAD SCIENCES : to Present at Upcoming Investor Conference
01.09.Pfizer, Merck launch new trials of oral COVID-19 drugs
01.09.Pfizer starts dosing patients in oral COVID-19 drug trial
1  2  3  4  5  6  7  8  9  10Weiter
Anstehende Termine für GILEAD SCIENCES, INC.